Anatomical Location and Metastasis Pattern of Intrapulmonary Lymph Nodes in NSCLC (ECTOP-1010)

Anatomical Location and Metastasis Pattern of Intrapulmonary Lymph Nodes in Non-small Cell Lung Cancer: a Multi-center, Prospective Observational Clinical Trial

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05094882

Enrollment

500

Registered

2021-10-26

Start date

2021-12-01

Completion date

2024-06-30

Last updated

2023-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma, Non-small Cell Lung Cancer

Keywords

Non-small Cell Lung Cancer, Intrapulmonary Lymph Nodes, Anatomical Location, Metastasis Pattern

Brief summary

This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1010. Anatomical Location and Metastasis Pattern of Intrapulmonary Lymph Nodes (Group 11-13) in Non-small Cell Lung Cancer: a Multi-center, Prospective observational Clinical Trial

Detailed description

Patients would be evaluated whether meet the criteria as clinical stage T1 non-small Cell Lung Cancer. Then, he/she would receive lobectomy. Finally, the detailed anatomical location of group 11-13 would be recorded immediately after surgery and their metastasis pattern would be explored in the follow-up period.

Interventions

PROCEDUREpulmonary lobectomy

resection of lung lobe

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

1. Preoperative examination showed patients with clinical T1 peripheral non-small cell lung cancer (NSCLC); 2. The lesion is located in a single lung segment or between two adjacent lung segments; 3. Perform radical lobectomy; 4. The preoperative examination did not reveal unresectable lymph nodes; 5. Have not received any other tumor-related treatments (including chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc.) before surgery; 6. No malignant tumor history; 7. No contraindications to surgery (ECOG score 0-1 points);

Exclusion criteria

1. Pathology revealed patients with non-T1 stage non-small cell lung cancer (NSCLC); 2. Radical lobectomy is not performed; 3. Acception of any anti-tumor treatment before surgery (excluding Chinese medicine treatment); 4. Refused to enter the group or asked to leave the group.

Design outcomes

Primary

Measure	Time frame	Description
metastasis rate of group 11-13 LN	one month after surgery	metastasis rate of intrapulmonary lymph nodes (group 11-13 LN) in non-small cell lung cancer

Secondary

Measure	Time frame	Description
detailed anatomical location	immediately after surgery	number of group 11-13 intrapulmonary lymph nodes in Non-small cell lung cancer and their detailed anatomical location

Countries

China

Contacts

Primary Contacthong hu

huhong0997@163.com86-13512102066

Backup ContactHong Hu

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026